CL2015003761A1 - Derivados de etinil como antagonistas de receptor metabotrópico de glutamato. - Google Patents

Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.

Info

Publication number
CL2015003761A1
CL2015003761A1 CL2015003761A CL2015003761A CL2015003761A1 CL 2015003761 A1 CL2015003761 A1 CL 2015003761A1 CL 2015003761 A CL2015003761 A CL 2015003761A CL 2015003761 A CL2015003761 A CL 2015003761A CL 2015003761 A1 CL2015003761 A1 CL 2015003761A1
Authority
CL
Chile
Prior art keywords
receptor antagonists
metabotropic receptor
glutamate metabotropic
glutamate
ethinyl
Prior art date
Application number
CL2015003761A
Other languages
English (en)
Inventor
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Eric Viera
Heinz Stadler
Rainer E Martin
Daniel Ruener
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2015003761A1 publication Critical patent/CL2015003761A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPUESTOS DERIVADOS DE ETINILO Y SUS SALES, COMO ANTAGONISTAS DE RECEPTOR METABOTRÓPICO DE GLUTAMATO; SU PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA EL TRATAMIENTO DEL ANSIEDAD, DOLOR, DEPRESION, ENFERMEDAD DE PARKINSON, ENTRE OTRAS.
CL2015003761A 2013-07-08 2015-12-30 Derivados de etinil como antagonistas de receptor metabotrópico de glutamato. CL2015003761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13175535 2013-07-08

Publications (1)

Publication Number Publication Date
CL2015003761A1 true CL2015003761A1 (es) 2016-07-15

Family

ID=48745843

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003761A CL2015003761A1 (es) 2013-07-08 2015-12-30 Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.

Country Status (27)

Country Link
US (2) US9682959B2 (es)
EP (1) EP3019486B1 (es)
JP (1) JP6116761B2 (es)
KR (1) KR101767348B1 (es)
CN (1) CN105358543B (es)
AR (1) AR096824A1 (es)
AU (1) AU2014289398B2 (es)
BR (1) BR112015029724A2 (es)
CA (1) CA2914282A1 (es)
CL (1) CL2015003761A1 (es)
CR (1) CR20150650A (es)
DK (1) DK3019486T3 (es)
EA (1) EA027882B1 (es)
ES (1) ES2628206T3 (es)
HU (1) HUE033270T2 (es)
IL (1) IL242682B (es)
MA (1) MA38659B1 (es)
MY (1) MY181847A (es)
PE (1) PE20160604A1 (es)
PH (1) PH12015502692B1 (es)
PL (1) PL3019486T3 (es)
SG (1) SG11201510607RA (es)
SI (1) SI3019486T1 (es)
TW (1) TWI527808B (es)
UA (1) UA116023C2 (es)
WO (1) WO2015004007A1 (es)
ZA (1) ZA201508410B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016273751B2 (en) * 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5724364A (en) * 1980-06-02 1982-02-08 American Cyanamid Co 2-(2-imidazoline-2-yl)pyridines and quinolines, manufacture and intermediate and herbicidal use
FI90869C (fi) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
AU2005336513B2 (en) * 2004-10-07 2012-08-09 Merck Sharp & Dohme Llc Thiazolyl mGluR5 antagonists and methods for their use
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
MY165141A (en) * 2011-04-26 2018-02-28 Hoffmann La Roche Pyrazolidin-3-one derivatives
EA022019B1 (ru) * 2011-04-26 2015-10-30 Ф.Хоффманн-Ля Рош Аг Этинильные производные в качестве положительных аллостерических модуляторов mglur5
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5

Also Published As

Publication number Publication date
DK3019486T3 (en) 2017-06-19
CR20150650A (es) 2016-01-11
AU2014289398A1 (en) 2015-11-26
AR096824A1 (es) 2016-02-03
JP6116761B2 (ja) 2017-04-19
CN105358543A (zh) 2016-02-24
MA38659B1 (fr) 2016-10-31
US20170217926A1 (en) 2017-08-03
EA201690162A1 (ru) 2016-05-31
ZA201508410B (en) 2017-08-30
SI3019486T1 (sl) 2017-07-31
HK1215573A1 (zh) 2016-09-02
TWI527808B (zh) 2016-04-01
MY181847A (en) 2021-01-08
HUE033270T2 (en) 2017-11-28
PE20160604A1 (es) 2016-07-03
ES2628206T3 (es) 2017-08-02
SG11201510607RA (en) 2016-01-28
WO2015004007A1 (en) 2015-01-15
UA116023C2 (uk) 2018-01-25
IL242682B (en) 2018-11-29
MA38659A1 (fr) 2016-02-29
TW201506019A (zh) 2015-02-16
EP3019486A1 (en) 2016-05-18
US9751856B2 (en) 2017-09-05
PH12015502692A1 (en) 2016-03-14
KR20160017026A (ko) 2016-02-15
BR112015029724A2 (pt) 2017-07-25
EA027882B1 (ru) 2017-09-29
US20160130255A1 (en) 2016-05-12
JP2016523939A (ja) 2016-08-12
AU2014289398B2 (en) 2018-02-01
PL3019486T3 (pl) 2017-08-31
PH12015502692B1 (en) 2018-08-24
US9682959B2 (en) 2017-06-20
CA2914282A1 (en) 2015-01-15
KR101767348B1 (ko) 2017-08-10
EP3019486B1 (en) 2017-04-12
CN105358543B (zh) 2018-06-12

Similar Documents

Publication Publication Date Title
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2016001895A1 (es) Compuestos
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
MX2017014375A (es) Moduladores del ccr2.
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
ECSP19062381A (es) Moduladores del receptor de estrógeno
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX367404B (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
UY36608A (es) Derivados de indol